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Abstract 43 
Background: Levels of high sensitivity troponin I (hs-cTnI) reflect myocardial stress. 44 
The role of hs-cTnI in predicting long term changes in the risk of cardiovascular 45 
disease (CVD) in general populations is not clearly defined. 46 
 47 
Methods: We investigate whether the change in three repeated measures of hs-cTnI 48 
collected five years apart in a prospective Danish study (3875 participants, initially 49 
aged 30-60, 51% female, disease free at baseline), improves 10-year prediction of 50 
incident CVD compared to using a single most recent hs-cTnI measurement. The 51 
change process was modelled using a joint (longitudinal and survival) model and 52 
compared to a Cox model using a single hs-cTnI measure adjusted for classic CVD 53 
risk factors, and evaluated using discrimination statistics.  54 
 55 
Results: Median hs-cTnI levels changed from 2.6ng/L to 3.4ng/L over 10 years. The 56 
change in hs-cTnI predicts 10-year risk of CVD (581 events); the joint model gave a 57 
HR 1.31 per interquartile difference in hs-cTnI (95% C.I. 1.15, 1.48) after adjustment 58 
for CVD risk factors. However, the joint model performed only marginally better (c-59 
index improvement 0.0041, p=0.03) than using a single hs-cTnI measure (c-index 60 
improvement 0.0052, p=0.04) for prediction of CVD, which is compared to a model 61 
incorporating CVD risk factors without hs-cTnI (c-index 0.744).   62 
 63 
Conclusions: The change in hs-cTnI in 5 year intervals better predicts risk of CVD 64 
in the general population, but the most recent measure of hs-cTnI, (at 10 years) is as 65 
effective in predicting CVD risk. This simplifies the use of hs-cTnI as a prognostic 66 
marker for primary prevention of CVD in the general population.   67 
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Introduction 77 
Cardiac troponin is a marker of necrosis and of myocardial infarction in emergency 78 
situations (1) but can also act as a long term biomarker in predicting risk of CVD, 79 
heart failure and death in the general population (2, 3). High sensitivity measured 80 
troponin I (hs-cTnI) can be detected in 80-90% of the general population (3, 4) and 81 
adds predictive information beyond established risk factors for fatal and non-fatal 82 
CVD in men and women across a wide age-range (2, 3, 5, 6). As low levels of 83 
troponin (below limits of conventional troponin assays) can be prognostically 84 
important (3), biological distributions and long term variation of troponin levels and 85 
their relationship with other risk factors across general populations need to be 86 
characterised. Longitudinal studies repeatedly measuring troponin can address this 87 
and estimate the prognostic importance of measuring changes for predicting risk of 88 
disease. The determinants of temporal increases in troponin (hs-cTnT) over 6 years 89 
in a general population (median 57 yrs) have recently been shown to include 90 
increasing age, male gender, hypertension, diabetes and obesity (7). Changes in 91 
troponin over 1 year were associated with increased risk of myocardial infarction in 92 
stable coronary heart disease patients (8). In healthy elderly populations (>65 years) 93 
changes in troponin over 3-5 years were associated with increased risk of heart 94 
failure, cardiovascular and all-cause mortality and atrial fibrillation (9, 10, 11, 12). 95 
However, incorporating this change led to minimal improvement in risk prediction (9, 96 
10, 11). In a healthy general population (mean 56 years) changes in troponin over 6 97 
years failed to improve prediction of coronary heart disease but improved heart 98 
failure risk (13). No studies have assessed the prognostic implications of changes in 99 
troponin levels in general populations over longer time scales.  100 
 101 
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Using a prospective population cohort initially aged 30-60, which collected hs-102 
cTnI and other risk factors at three time points over 10 years with a further 16 years 103 
of follow up for incident CVD events, we determine 1) if change in hs-cTnI is 104 
associated with increased risk of CVD, and 2) whether prediction of CVD can be 105 
improved by modelling change in hs-cTnI. We develop prognostic models comparing 106 
the trend in hs-cTnI over 10 years to a single most recent hs-cTnI measure.  107 
 108 
Methods 109 
 110 
Study design 111 
The MONICA 1 population cohort at the Research Centre for Prevention and Health 112 
(RCPH) represents 11 municipalities in Copenhagen, Denmark. Men and women 113 
aged 30, 40, 50 and 60 were randomly sampled from the national population register 114 
(14). They were examined in 1982-84 (Round 1), then re-examined in 1987-1988 115 
(Round 2) and again in 1993-1994 (Round 3) (14) (Figure 1). Participants received a 116 
physical examination, a self-administered questionnaire, and a blood sample was 117 
drawn at each exam. Smoking status, blood pressure, body mass index and blood 118 
lipids were measured in a standardized way. Prevalent diabetes was defined as self-119 
reported doctor-diagnosed diabetes, use of diabetes medication or diabetes history 120 
recorded in registry data at each round. The study was approved by ethics 121 
committees; participants consented to all examinations and follow-up of their medical 122 
records. At recruitment, pre-existing cardiovascular disease (myocardial infarction or 123 
stroke) was self-reported. The outcome was the first major cardiovascular event 124 
(including first fatal or non-fatal definite or possible myocardial infarction, coronary 125 
death or unclassifiable death, unstable angina, cardiac revascularisation, and 126 
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probable ischemic stroke). Follow up was achieved through linkage to the National 127 
Cause of Death Register and National Hospital Discharge Register until December 128 
2009 with only 40 participants (1.05%)lost to follow-up (15, 16). Registry diagnoses 129 
have been validated against the MONICA criteria (17). 130 
 131 
Biomarker measurements and adjustments 132 
Serum was separated from blood, then stored at 4ºC (1-3 days) during transfer to the 133 
laboratory for storage at -20ºC and subsequently at -80 ºC. Storage times are 134 
summarized in Supplemental table 1. Biomarkers were measured in the 135 
MORGAM/BiomarCaRE laboratory. hs-cTnI levels were determined by the 136 
ARCHITECT STAT high sensitivity Troponin I immunoassay (Abbott Diagnostics, 137 
USA, ARCHITECT i2000SR). The limit of detection (LoD) was 1.9 ng/L, with values 138 
below this imputed (see below). The assay supported a 10% coefficient of variation 139 
at a concentration of 5.2 ng/L. Intra-assay and inter-assay coefficients of variation 140 
were 4.3% and 6.3%. Because of skewed distributions, a cubic root transformation 141 
was applied to hs-cTnI for consistency with previous research (2, 3).  142 
 143 
Statistical Analysis 144 
 145 
Missing data occurred across the three rounds either due to participants failing to 146 
attend examination, insufficient information on risk factors or insufficient serum for a 147 
biomarker test. However their vital status was followed up. Participation rates across 148 
the rounds are given in Supplemental table 2. Missing data for risk factors was 149 
minimal (<0.1%) for those attending exams. Missing data for biomarkers ranged from 150 
0.15% to 8.8% and hs-cTnI missingness was from 4.8% at round 1, 8.8% at round 2 151 
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and 0.51% at round 3. Missing data was addressed through a multiple imputation 152 
(MI) model which captured the longitudinal trajectory of hs-cTnI and other variables. 153 
Imputed values were applied to the risk prediction analysis models. Individuals 154 
recruited at round 1 were included in the imputation model.  The MI model for men 155 
and women combined included classic CVD risk factors, biomarkers, and case 156 
status at the start and end of the follow-up. Twenty imputed datasets were created 157 
using chained equations (18). Predictive mean matching was used for all variables, 158 
except hs-cTnI, where a normal linear regression model was used. When the 159 
missing values corresponded to values below the LoD the imputed values were 160 
drawn from a truncated normal distribution, otherwise the imputed values were 161 
drawn from a normal distribution. Time-to-event information was included in the 162 
imputation model (19) with further details in supplemental material. A sensitivity 163 
analysis was performed on a restricted dataset of those with hs-cTnI and risk factors 164 
measured at round 3, who may have had some missing measures prior to that 165 
round, which were imputed (see supplemental methods). 166 
 167 
Prediction models 168 
 169 
Prediction modelling is outlined in Figure 1. We develop prognostic models 170 
comparing the trend in hs-cTnI over 10 years to a single most recent hs-cTnI 171 
measure. We need to keep the measurement period (10 years of change) separate 172 
to the follow-up period as prognostic models cannot use ‘future measures’ (i.e. R2 or 173 
R3 in this case) as predictors, therefore a new baseline at 10 years becomes the 174 
starting point for predictions using a further 16 years of follow-up after this point.  175 
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 A Cox proportional hazards model was constructed containing 176 
cardiovascular risk factors: sex, systolic blood pressure (SBP), HDL-cholesterol, 177 
nonHDL-cholesterol (difference between total and HDL cholesterol), prevalent 178 
diabetes, smoking status and body mass index (BMI) measured at round 3 (Model 179 
1). The round 3 measurements were the baseline for the follow-up and age was 180 
used as the time-scale in the analysis. The follow-up extended up to 16 years later. 181 
To this model, hs-cTnI measured at round 3 was added (Model 2). Hazard ratios are 182 
reported per 0.4 times the cubic root of the hs-cTnI concentration in ng/L which 183 
corresponds roughly to the interquartile range in the cohort.  184 
 Model 2 is compared to models 3-5 which incorporate the history of hs-185 
cTnI and the cardiovascular risk factors measured in rounds 1-3. Model 3 is similar 186 
to model 2 but uses the change in hs-cTnI from round 1 to 3 as the predictor instead 187 
of the level of hs-cTnI at round 3. Those developing CVD before Round 3 were 188 
excluded from analysis.  189 
 190 
Model 4 combines analysis of the repeated measurements and time to 191 
cardiovascular event. It is a joint model (JM) of the association between the repeated 192 
measurements at rounds 1-3 and the risk of CVD (20). The model forms two parts, a 193 
multilevel model for longitudinal trend in hs-cTnI and a proportional hazards survival 194 
model for cardiovascular events (supplemental equation). The multilevel model 195 
includes a random intercept reflecting a different starting value of hs-cTnI for each 196 
participant and its relationship with other covariates, and a random slope for time 197 
from baseline. Sex, age at the first examination (measuring the cross sectional effect 198 
of age) and time from baseline (measuring the longitudinal effect of age) are fixed 199 
effects in this model.  The survival model incorporates: sex, SBP, HDL-cholesterol, 200 
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nonHDL-cholesterol, prevalent diabetes, smoking status and BMI, updated at each 201 
round. hs-cTnI is included in the survival model via the estimate from the multilevel 202 
model. The JM was fitted to all follow-up data but the validation step involving Model 203 
4 uses only the follow-up data after round 3 (see below).   204 
 205 
We also fitted a Cox model with time-dependent covariates using the same 206 
covariates as Model 4 and using the same timespan and number of events (Model 207 
5). All survival models used age as the time scale (21, 22). For the Cox models, 208 
those developing CVD before R3 were excluded. For the joint models information 209 
available after an individual developed CVD was not used. Prevalent cases of CVD 210 
at the first examination (2.18%, N=83) were excluded from the analyses. 211 
 212 
Fitting and validation of the prediction models 213 
 214 
Prediction models 1-5 were discriminated using the C-index (23) and net 215 
reclassification index (NRI) (24) using the 10 year probabilities of CVD derived from 216 
the models using round 3 as the baseline. Ten-fold cross validation was used to 217 
adjust the risk estimates for over optimism in assessing model performance on the 218 
same dataset where it was developed (25, 26). The analyses were carried out in 219 
both genders combined, and performed using R v3.1.1 (R Core Team (2013) (27). 220 
Our study conforms to TRIPOD guidelines for reporting prediction models (28). 221 
 222 
 223 
Results 224 
 225 
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Participant characteristics 226 
 227 
Participant characteristics for each examination round are given in Table 1 (imputed 228 
data) and Supplemental table 1 (complete case data). From round 1 (R1) to round 3 229 
(R3), the prevalence of diabetes increased from 2.2% to 4.3%, smoking decreased 230 
from 46.7% to 39.5%, blood pressure treatment increased from 5.8% to 12.5% and 231 
systolic BP increased from 123.3 to 129.9mmHg.   232 
 233 
hs-cTnI ranged from 0 to 173.0 ng/L at R1 to 0.3 to 164.6ng/L at R3. Median 234 
hs-cTnI levels changed from 2.6ng/L to 3.6ng/L to 3.4ng/L across the three rounds, 235 
with overall changes illustrated in Figure 2. hs-cTnI was above the LoD (>1.9ng/L) in 236 
68.2% of participants at R1 (61.8% men, 38.2% women), 90.4% at R2 (50.8% men, 237 
49.2% women), and 84.9% at R3 (55.1% men, 44.9% women). 95% of the changes 238 
in hs-cTnI from R1 to R3 are relatively small, between -3.5 and 6.48ng/L 239 
(Supplemental table 3). Higher levels of hs-cTnI were observed in men, but over time 240 
hs-cTnI increased in both genders. hs-cTnI values increased over time from R1 to 241 
R2 in the full cohort and continued to increase in CVD cases, reaching a plateau in 242 
non-cases from R2 to R3 (Supplemental figure 1).  243 
 244 
Spearman’s correlation coefficient for hs-cTnI from R1 to R3 ranged from 0.59 245 
to 0.69. (R1 to R2 ρ=0.60, R2 to R3 ρ=0.69, R1 to R3 ρ =0.59). This range was 246 
similar although lower than correlations observed for SBP across three rounds (R1 to 247 
R2 ρ=0.76, R2 to R3 ρ=0.75, R1 to R3 ρ=0.67) or HDL cholesterol (range 0.75 to 248 
0.81), correlations for BMI across rounds were higher (range 0.85 to 0.91). For the 249 
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prediction models, the number of participants for each risk set after exclusions is 250 
given in Supplemental table 4. 251 
 252 
Association of history of change in hs-cTnI levels and CVD 253 
 254 
During the follow-up period after round 3 (1993-94, median follow-up 16.6 years), 255 
444 participants had a CVD event. hs-cTnI at R3 was a strong predictor of risk of 256 
CVD (HR 1.18 per interquartile difference in the cubic root of hs-cTnI (95% C.I.1.08, 257 
1.30; p<0.001) after adjustment for cardiovascular risk factors (Model 2 in Table 2 258 
and  Supplemental table 5). The 10-year change in hs-cTnI (difference R3-R1), after 259 
adjustment for risk factors was also positively associated with CVD (HR 1.16; 95% 260 
C.I. 1.02, 1.31; p=0.023) (Model 3 in Table 2 and Supplemental table 5). 261 
 262 
Association of longitudinal trend in hs-cTnI levels with CVD 263 
 264 
During the follow-up after round 1 (median follow-up 27.5 years) 581 incident CVD 265 
cases were observed. After risk factor adjustment, hs-cTnI was positively associated 266 
with CVD in the joint model, with a hazard ratio of 1.31 (95% C.I. 1.15, 1.48), per 267 
interquartile difference in the cubic root; p<0.001 (Model 4 in Table 2 and Table 3). 268 
The Cox model with time dependent covariates yielded a HR of 1.22 (95% C.I. 1.12, 269 
1.32) p<0.001 (Model 5 in Table 2 and Supplemental table 5). Both these models 270 
account for changing levels of cardiovascular risk factors and hs-cTnI at each round.   271 
According to the longitudinal part of the joint model, hs-cTnI increased with 272 
age at round 1 by 0.007 (95% C.I. 0.006, 0.008, p<0.001) cube units and with time 273 
from baseline (coefficient 0.016, 95% C.I. 0.014, 0.017, p<0.001). hs-cTnI was 274 
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higher in men than women by 0.226 (C.I. 0.205, 0.247, p<0.001) cube units (Table 275 
3).  276 
 277 
Prediction modelling for troponin 278 
The probabilities of 10-year risk of CVD were estimated from the Cox models based 279 
on 444 CVD events. The c-index for model 1 with cardiovascular risk factors was 280 
0.744 (95% C.I. 0.717, 0.772). Adding a single most recent hs-cTnI measurement at 281 
round 3 (i.e. Model 2) to this, marginally improves prediction (c-index 0.750, 282 
improvement 0.0052 p=0.043) (Table 4). Model 3, replacing the last hs-cTnI 283 
measurement with the 10-year change in hs-cTnI, does not improve prediction upon 284 
the single measure of hs-cTnI (Model 2). Model 4, the JM incorporating the 285 
longitudinal trend in hs-cTnI and risk of CVD, improves prediction but only marginally 286 
when compared to Model 2. The c-index for Model 4 was 0.754 (95% C.I. 0.726, 287 
0.782), improvement 0.004 p=0.03) compared to Model 2 (Table 4). The continuous 288 
NRI measure for Model 4 was 0.23 (p<0.001) when compared to Model 2.  289 
 290 
Sensitivity analysis 291 
  292 
Sensitivity analysis based on those with hs-cTnI and risk factors measured at round 293 
3 (N=2339) are presented in Supplemental Tables 6-7. After risk factor adjustment, 294 
hs-cTnI was positively associated with CVD in the JM with a HR of 1.30 (95% C.I. 295 
1.15, 1.47) per interquartile difference in cubic root of hs-cTnI (Supplemental table 296 
6). The addition of hs-cTnI measured at round 3 to cardiovascular risk factors (Model 297 
2) failed to improve prediction, based on 304 CVD events, (c-index improvement 298 
0.004, p=0.089), when compared to Model 1, whose c-index was 0.755 299 
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(Supplemental table 7). None of the models incorporating change in hs-cTnI 300 
improved prediction when compared to the model with a single measure of hs-cTnI 301 
at round 3. (Supplemental Table 7). See Supplemental methods for further details. 302 
 303 
Discussion 304 
We questioned whether monitoring changes in troponin over time in general 305 
populations could lead to better prediction of future CVD events compared to a 306 
single measure of hs-cTnI. Our novel approach focused on 10-year risk of CVD, an 307 
established metric in CVD risk scores so we could make a realistic comparison 308 
between a single measure to longitudinal measures. We tested this in a longitudinal 309 
cohort with clear separation between measurement period (10 years of change in hs-310 
cTnI) and follow-up period used for prediction (16 years) as prognostic models 311 
cannot use ‘future’ measures as predictors. Therefore a new ‘baseline’ at 10 years 312 
became the starting point for predictions. Our study had longer intervals of 313 
measurement than comparable studies (9, 10) and with larger number of events (9) 314 
and we used a joint modelling (JM) approach which more sensitively monitored the 315 
change in hs-cTnI (M4) than incorporating change as a predictor in the models (M3). 316 
We found that hs-cTnI increases over time in the general population and the change 317 
in hs-cTnI is associated with increased risk of fatal and non-fatal CVD. Our findings 318 
applied across a wide age range including a younger group, while previous findings 319 
for association of change in hs-cTnI or hs-cTnT with increased risk of heart failure, 320 
cardiovascular death and all-cause mortality are evident in older groups (>65 years) 321 
(9, 10) and a middle-aged group for coronary heart disease (13).We found three 322 
measures of hs-cTnI can be better than one in characterising risk of CVD and 323 
improving prediction. In terms of risk prediction in the general population, however, 324 
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the magnitude of the gain is minimal and offers no significant practical advantage 325 
over a single most recent measure of hs-cTnI for long term prediction of CVD risk. 326 
 327 
 The associations show that change in hs-cTnI is significantly linked with 328 
cardiovascular disease, confirming previous reports of association with 329 
cardiovascular mortality (10) and coronary heart disease (13). Rather than 330 
categorising troponin like these studies, which may reduce precision and power (29), 331 
we used a continuous measure. Our associations are significant and have tighter 332 
confidence intervals based on a sample of N=3178 compared to N=1797 (10) or 333 
N=3448 (13). Moreover the HR of continuous hs-cTnI is not directly comparable to 334 
the HRs of categorical variables. The associations showed that the change in hs-335 
cTnI incorporated to the JM had a highly significant independent effect if added after 336 
other updated risk factors, highlighting its prognostic value independently of other 337 
risk factors. We quantified the impact of change in hsTnI compared to change in 338 
systolic BP on prediction of CVD (see supplemental methods). The change in SBP 339 
contributes twice as much to prediction of CVD than change in hsTnI (measured in 340 
relative contributions to the JM), which is unsurprising as SBP is a key modifiable 341 
risk factor for CVD, yet hsTnI eclipses some established risk factors such as HDL 342 
cholesterol and BMI in its impact. hs-cTnI and change in hs-cTnI offer the potential 343 
for identifying individuals at higher risk of CVD events but not currently identified by 344 
established risk factors.  345 
 346 
Our statistical approach was sensitive enough to detect significant 347 
improvements in risk prediction by monitoring changes in hs-cTnI compared to a 348 
single measure. JM sensitivity may be a result of including the CVD outcome when 349 
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estimating the longitudinal hs-cTnI trend, which avoids diluting the association 350 
between hs-cTnI and CVD, while Cox time-dependent models tend to underestimate 351 
the true risk for hs-cTnI (30, 31). However, median hs-cTnI levels were relatively low 352 
from 2.6ng/L to 3.4ng/L over 10 years, but followed predictable trends. Levels 353 
frequently changed (7, 9, 10, 32), even though most had levels below diagnostic 354 
cutoffs for myocardial infarction (4, 7, 33). hs-cTnI levels across rounds were 355 
correlated and similar to other cardiovascular risk factors such as systolic BP but 356 
lower than BMI suggesting strong tracking over time. Detectable hs-cTnI levels 357 
increased from 68% at round 1 to 84.9% at round 3, consistent with levels in other 358 
general populations (2, 3, 4) and in a previous longitudinal study (7). hs-cTnI levels 359 
increased with age and it may be that the single last measure of hs-cTnI was 360 
sufficient for optimal prediction as this represented a time when hs-cTnI could 361 
become prognostically more relevant as the population aged. Other studies have 362 
found minimal benefit of incorporating change in hs-cTnI/hs-cTnT to prediction but 363 
have taken different statistical approaches and outcomes precluding a direct 364 
comparison. McEvoy et al. (13) compared a model with CVD risk factors 365 
incorporating the delta change in TnT from 2 measurements, 6 years apart, N=3448, 366 
including 622 CHD events. They found the addition of change in hsTnT offered no 367 
significant gain in discrimination (c-index difference 0.0004, p value 0.1). This is 368 
consistent with our adjusted model including delta change in hs-cTnI (Table 4, c-369 
index difference -0.003, p=0.11) although the models are not directly comparable 370 
given the different troponin measurements and statistical approaches. However, they 371 
do find that incorporating the change in TnT improved prediction of heart failure and 372 
all-cause mortality (13). In older cohorts minimal predictive benefits have also been 373 
found. deFilippi et al. incorporated relative change in hsTnT over 2 years as a 374 
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covariate in a Cox model marginally improved classification (IDI) for heart failure and 375 
cardiovascular mortality but not c-index in an elderly cohort with ~8 years follow-up 376 
(10). Eggers et al. incorporated relative change in hs-cTnI over 5 years as a time-377 
dependent covariate in a Cox regression with ~4 years follow-up, finding that this 378 
failed to improve discrimination of cardiovascular mortality (N=32 events) in an 379 
elderly cohort (>65 years) (9). Taking a similar approach in this cohort, the change in 380 
hs-cTnI was found to be less strongly associated with cardiovascular events (N=163) 381 
than the change in GDF15 or NTProBNP (11). The change in hs-cTnI was compared 382 
against baseline hs-cTnI or not formally compared prognostically against a single 383 
last measure (9, 10, 11). Our paper by comparison, has unequivocally tested 384 
whether the change in troponin adds prognostic information to 10-year risk models 385 
compared to a single hs-cTnI measure and has laid a framework for testing in other 386 
cohorts.  387 
 388 
 389 
Missing data is a study limitation for longitudinal studies and it is difficult to 390 
distinguish data missing at random from missing not at random. Multiple imputation 391 
maximised the inclusion of relevant information for the prediction models. Omitting 392 
information from subjects with missing data can attenuate associations and cause 393 
bias (34), as we observed in a sensitivity analysis when we restricted the dataset to 394 
those available at round 3. We cannot exclude the possibility that sample 395 
degradation may have affected the biomarker measurements leading to 396 
overestimation of the change in hs-cTnI. However, previous studies have found that 397 
hs-cTnI assessment is robust to long term storage (3) and if specimens deteriorated 398 
at the same rate it should not affect the predictive value of hs-cTnI in the models 399 
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even if absolute levels are affected. Changes in medication use over 26 years may 400 
have affected the predictive value of hs-cTnI over time but little empirical data on 401 
such effects exist.  402 
In summary, while a change in hs-cTnI improved prediction, it did not 403 
substantially improve estimates beyond a single most recent measure of hs-cTnI. A 404 
single measure of hs-cTnI is sufficient for 10-year prediction of CVD risk, simplifying 405 
the use of hs-cTnI as a stable prognostic marker for primary prevention of CVD and 406 
endorses prediction models of hs-cTnI for 10-year risk of CVD derived from other 407 
larger general population studies (2, 3). However, other factors such as physical 408 
activity (35), hyperglycemia (7, 36) and renal function (37) can influence changes in 409 
hs-cTnI. Further work will examine the potential for hs-cTnI to monitor changes in 410 
risk for the selection of higher risk subjects and targeting of therapy (6, 38).  411 
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Table 1 Participant characteristics of the study population according to examination 582 
round they were collected in. 583 
Risk factors  ROUND 1 (N=3785) ROUND 2 (N=3672) ROUND 3 (N=3461) 
Examination age (years) 45.5±11.0 50.2±11.0 55.6±10.9 
Gender (No. of men) 1940 (51.3%) 1867 (50.8%) 1726 (49.9%) 
BMI (kg/m²) 24.6±3.9 25.2±4.0 26.0±4.3 
Systolic BP (mmHg) 123.3±16.8 126.5±19.0 129.9±19.4 
HDL cholesterol (mmol/L) 1.5±0.4 1.5±0.4 1.4±0.4 
Total cholesterol (mmol/L) 5.8±1.2 6.1±1.2 6.2±1.1 
Antihypertensive meds 221 (5.8%) 167 (4.6%) 434 (12.5%) 
Diabetes 86 (2.3%) 121 (3.3%) 145 (4.2%) 
Daily smoker 1768 (46.7%) 1829 (49.8%) 1366 (39.5%) 
hs-cTnI (ng/L) 2.6 (1.6, 4.0) 3.6 (2.6, 5.0) 3.4 (2.3, 4.8) 
Creatinine (mg/dL) 0.8 (0.7, 0.9) 0.8 (0.7, 0.9) 0.8 (0.7, 1.0) 
CRP (mg/L) 1.2 (0.6, 2.8) 1.2 (0.6, 2.9) 1.5 (0.7, 3.5) 
    
    
 584 
Mean (±SD), median (first quartile, third quartile) or Numbers (%). Data are derived 585 
from the multiple imputed datasets. HDL high density lipoprotein cholesterol, BP blood 586 
pressure, hs-cTnI high sensitivity troponin I, CRP c-reactive protein, eGFR estimated 587 
glomerular filtration rate.  588 
 589 
 590 
Table 2 Summary of the association between hs-cTnI and risk of CVD 591 
  592 
Model HR (95% C.I.) p-value 
Model 2 (hs-cTnI at R3)  1.18 (1.07, 1.30) <0.001 
Model 3 (hs-cTnI delta change R1, R3)  1.16 (1.02, 1.31) 0.023 
Model 4 (joint model) 1.31 (1.15, 1.48) <0.001 
Model 5 (time dependent covariates) 1.22 (1.12, 1.32) <0.001 
 593 
Hazard ratios for hs-cTnI in Models 2 and 3 are based on 3178 individuals and 444 594 
CVD events. Model 2 is based only on hs-cTnI at round 3. Hazard ratios for hs-cTnI 595 
in Models 4 and 5 are based on 3702 individuals and 581 events. Models 4 and 5 596 
28 
 
account for changing levels of hs-cTnI and other risk factors. HRs are reported as 597 
per interquartile difference and adjusted for cardiovascular risk factors.   598 
 599 
 600 
 601 
 602 
 603 
 604 
 605 
  606 
  607 
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Table 3 The joint model of longitudinal trend in hs-cTnI (Model 4) 608 
Longitudinal submodel for hs-cTnI (from the joint model). 609 
  hs-cTnI1/3 (95% C.I) p-value 
(Intercept) 1.004 (0.943, 1.065) < 0.001 
Time from baseline (years) 0.016 (0.014, 0.017) < 0.001 
Age at round 1 (years) 0.007 (0.006, 0.008) < 0.001 
Male 0.226 (0.205, 0.247) < 0.001 
 610 
Survival submodel (from the joint model).  611 
  
All (N=3702, 581 
events)  
  HR (95% C.I.) p-value 
hs-cTnI1/3  1.31 (1.15, 1.48) < 0.001 
Male 1.73 (1.43, 2.09) < 0.001 
BMI (kg/m²) 0.98 (0.96, 1.01) 0.15 
Systolic BP (mmHg) 1.01 (1.01, 1.02) < 0.001 
HDL cholesterol (mmol/L) 0.62 (0.46, 0.82) 0.0012 
Non-HDL cholesterol (mmol/L) 1.20 (1.12, 1.29) < 0.001 
Diabetes 1.73 (1.25, 2.40) < 0.001 
Daily smoker 1.80 (1.49, 2.17) < 0.001 
 612 
The joint model comprises two parts: The longitudinal submodel for the change in 613 
hs-cTnI over time using a random intercept for hs-cTnI. hs-cTnI is incorporated into 614 
the survival submodel via the estimate from this intercept. The survival (relative risk) 615 
submodel incorporates the time dependent changes in hs-cTnI and other risk factors 616 
across the 3 rounds. N number of participants and CVD events. HRs per interquartile 617 
difference in the cubic root of hs-cTnI.  618 
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Table 4 Risk models describing the improvement of 10-year risk prediction for cardiovascular disease by hs-cTnI in all participants. 619 
 all (N=3178)      
  c-index difference p value 
cont. 
NRI p value     
Model 1 Cardiovascular risk factors (RF) 0.744         
Model 2 (hs-cTnI at R3) + RF 0.750 0.0052 0.043 0.194 0.043     
Model 3 (hs-cTnI delta change R1, R3) + RF  0.746 -0.003 0.110 -0.162 0.033     
Model 4 (hs-cTnI joint model) + RF 0.754 0.004 0.030 0.230 <0.001     
 620 
Cardiovascular risk factors (RF) include sex, BMI, SBP, HDL and nonHDL-cholesterol, diabetes and daily smoking. R1 round 1, R3 621 
round 3. Note that Models 3 and 4 are compared to Model 2 (i.e. Model 2 becomes the base model for these comparisons). 622 
Discrimination for 10-year risk prediction is based on 3178 individuals and 444 CVD events.  623 
 624 
 625 
 626 
 627 
 628 
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Figure captions:  629 
Figure 1 Study design of the prospective Danish cohort.  630 
Figure 1 Legend: Data were collected at three rounds of examination over 10 years 631 
with 26 year follow-up. Number of individuals attending exam are given, some 632 
individuals missed an exam and some had an incident event (indicated by 633 
abscent/blue).  Number of exam participants, number of participants failing to attend 634 
exam plus numbers of missing data on covariates for those that did attend the exam. 635 
All individuals recruited at R1 were included in the multiple imputation model, see 636 
methods. Prognostic modelling; We compared a prognostic model with a single last 637 
measure of hs-cTnI and risk factors (smoking, blood pressure, prevalent diabetes, 638 
HDL and nonHDL cholesterol, BMI) to a model containing only risk factors. Then we 639 
compared the model with 10-year change in hs-cTnI and risk factors (incorporated 640 
into a joint model) to the model with single measure of hs-cTnI and risk factors.  641 
 642 
Figure 2 Spaghetti plot visually illustrating the change in hs-cTnI over time. 643 
Figure 2 legend: Each line represents a participant’s hs-cTnI values changing over 3 644 
rounds/10 years. The trend (blue line) shows an increase in hs-cTnI over time with 645 
increasing age in both genders. Lines shown are slightly transparent so that regions 646 
that appear darker have more points plotted on them. The blue line indicates a loess 647 
smoothing line of best fit to the data.  648 
 649 
